AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

Novel Biologics. Designed by Evolution. Discovered by AI.

AMPLY Discovery uses machine learning and synthetic biology to mine vast biological data to discover novel biologic drug and nutraceutical candidates. Using a proprietary in silico and in vitro hybrid platform to discover best-in-class molecules AMPLY is helping tackle some of humankind's greatest challenges such as cancer, MDR infections and metabolic diseases.

Based in Belfast, Northern Ireland. Spin out from Queen's University Belfast.

Innovate UK

Co-FundNI

QUBIS Innovation Fund

Halo Business Angel Network

Helix Way

Explain the AMPLY Discovery platform to a non-scientist!

Dr Ben Thomas describes how the AMPLY Discovery technology uses AI to speed up the process of finding new effective ways to kill disease threats.

Bacterial infections could kill 10 million a year by 2050, so we need faster ways to develop new drugs. AMPLY Discovery is at the forefront of groundbreaking new technologies, combining AI, genomics and synthetic biology.

Read our carousel to understand more!

#amplydiscovery #ai #drugdiscovery #startup


AMPLY Discovery will be one of the leading NI-based start ups pitching at the Deep tech Summit in Belfast on 16th November. 

We look forward to catching up with friends and talking about our drug discovery programmes with investors. 

If you want to catch up, or fancy a nice night out in Belfast you can register to attend. Anne Dornan Dr. Cecilia Hegarty Paul Donachy QUBIS Ltd Brian McCaul https://lnkd.in/eUGESxVT 

We are thrilled to share that AMPLY Discovery has been selected as one of 12 “exceptional AI startups”, to participate in the Techstars Chicago, powered by J.P. Morgan program. 

This accelerator is for early-stage companies that use Artificial Intelligence to address global problems, scale businesses, and design new business models.

We will have the chance to work alongside some of the brightest minds, receive world-class mentorship, and access invaluable resources to accelerate the growth of Amply Discovery.

Here’s a comment from Tricia Martínez-Saab, Managing Director of Techstars. 

“Artificial Intelligence is revolutionary technology that can be used as a tool to fight some of our greatest challenges. Now more than ever we need novel innovative out of the box solutions that can move the needle. Our 12 portfolio companies for Techstars Chicago powered by J.P. Morgan are pushing the boundaries on what is possible with Artificial Intelligence.” 

We look forward to sharing our progress, insights, and learnings along the way.

Please feel free to reach out if you'd like to connect or collaborate!

#AI #syntheticbiology #StartUp #AcceleratorProgram


msh id	COM:AMPLYDISCOVERY
symbol	-
name	AMPLY Discovery
homepage url	https://amplydiscovery.com
country	GB
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	7
crunchbase url	https://www.crunchbase.com/organization/amply-discovery
linkedin url	-
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	9.97
growth score 28	6.64
growth score 90	6.3
growth score 365	34.06

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:AMPLYDISCOVERY

AMPLY Discovery

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-